Overall Revenue (Q1 2024)

29% YoY increase "

This growth was driven by strong performance across segments including a 126% jump in Rare Disease, 10% growth in Generics, and a 13% uptick in Established Brands, reflecting expanded market reach and operational efficiency. " " " " " "

Rare Disease Segment – Purified Cortrophin Gel (Q1 2024)

126% YoY increase " " " "

The surge was due to increased prescription volumes, expansion into new specialties such as pulmonology and ophthalmology, and the product innovation with a new 1 mL vial size targeting acute conditions. " " " "

Generics Segment (Q1 2024)

10% YoY increase " " " "

Growth in the generics segment was driven by increased base volumes and the successful launch of new products, including a Competitive Generic Therapy with 180-day exclusivity. " " " "

Established Brands (Q1 2024)

13% YoY increase " " "

The increase in this segment was supported by higher sales volumes and favorable supply chain tailwinds, contributing positively to overall revenue. " " "

Generics Segment (Q1 2025)

40.5% YoY increase to $98.7 million " " "

This robust growth was fueled by markedly increased volumes and successful new product launches, such as the market-first prucalopride tablets with 180-day exclusivity, outperforming prior period performance in this segment. " " "

Rare Disease – Cortrophin Gel (Q1 2025)

43.1% YoY increase to $52.9 million " " " "

Growth in this metric was driven by a record number of new patient starts and sustained high prescription volumes, signaling continued strength compared to the previous period's performance despite a moderated rate. " " " "

Rare Disease Overall (Q1 2025)

86.7% YoY increase to $69.0 million " " "

This overall increase reflects both strong organic growth and strategic impacts such as the Q3 2024 Alimera acquisition, which contributed $16.1 million in revenues, further consolidating gains from previous periods. " " "

Brands Portfolio (Q1 2025)

–2.2% YoY decrease to $25.1 million " "

The slight decline suggests potential market saturation or a strategic shift in focus, possibly as resources were reallocated towards the higher-growth Generics and Rare Disease segments, contrasting with the strong growth observed in earlier periods. " "